Litigation Details for Monsanto Company v. Syngenta Seeds Inc. (D. Del. 2004)

Monsanto Company v. Syngenta Seeds Inc. (D. Del. 2004)

Docket		Date Filed	2004-05-12
Court	District Court, D. Delaware	Date Terminated	2008-05-23
Cause	28:1338 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	Both	Referred To
Parties	JC ROBINSON SEEDS, INC.
Patents	8,939,943
Attorneys	Karen Elizabeth Keller
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for Monsanto Company v. Syngenta Seeds Inc. (D. Del. 2004)

Date Filed	Document No.	Description	Snippet	Link To Document
2004-05-12				External link to document

Monsanto Company v. Syngenta Seeds Inc. Litigation Summary, 1:04-cv-00305

Last updated: August 31, 2026

Monsanto Company v. Syngenta Seeds Inc., No. 1:04-cv-00305, was a U.S. District Court for the District of Delaware patent dispute concerning genetically modified, glyphosate-resistant crop technology. Monsanto asserted U.S. Patent No. 5,352,605, which covered methods and biological materials associated with glyphosate-resistant plants. The dispute reached the U.S. Court of Appeals for the Federal Circuit, which issued a precedential decision at 503 F.3d 1352 in 2007.

The principal issue was whether Monsanto’s patent specification adequately described and enabled the broad scope of the claimed glyphosate-resistance technology, including the technology used in Syngenta’s genetically modified corn. The litigation is important for biotechnology patent strategy because it addressed the written-description and enablement requirements for broad genus claims in agricultural biotechnology.

What patents were at issue in Monsanto v. Syngenta Seeds?

The central patent was U.S. Patent No. 5,352,605, assigned to Monsanto. The patent concerned glyphosate-resistant plants and genetic constructs involving glyphosate-resistant forms of 5-enolpyruvylshikimate-3-phosphate synthase, commonly known as EPSPS.

Item	Detail
Patent	U.S. Patent No. 5,352,605
Patent holder	Monsanto Company
Technology	Glyphosate-resistant plants and EPSPS-related genetic technology
Defendant	Syngenta Seeds Inc.
District court	U.S. District Court for the District of Delaware
District docket	No. 1:04-cv-00305
Federal Circuit decision	503 F.3d 1352 (Fed. Cir. 2007)
Technology category	Agricultural biotechnology and genetically modified seed
Commercial field	Herbicide-tolerant corn and related crop products

The asserted patent was not a pharmaceutical patent. It did not concern a drug substance, pharmaceutical formulation, biologic, medical-use claim, or drug-delivery system.

What was Monsanto’s infringement theory?

Monsanto alleged that Syngenta’s glyphosate-resistant crop technology infringed claims of the ’605 patent. Monsanto’s position was that Syngenta’s genetically modified crop products and associated genetic constructs fell within the patent’s claims because they used glyphosate-resistant EPSPS technology.

The dispute involved the scope of Monsanto’s claims. Monsanto sought protection broad enough to cover glyphosate-resistant plant systems beyond the specific embodiments described in the patent specification. Syngenta challenged that breadth, arguing that Monsanto’s disclosure did not support the full scope of the asserted claims.

The case therefore combined infringement questions with validity defenses. Syngenta’s principal challenge was that Monsanto could not claim a broad genus of glyphosate-resistant biological materials based on the narrower disclosure in the patent specification.

What did the District of Delaware decide?

In 2006, the District of Delaware issued an opinion reported at 443 F. Supp. 2d 636. The district court addressed the patent’s claim scope and the adequacy of Monsanto’s disclosure under 35 U.S.C. § 112.

The court’s analysis focused on whether Monsanto’s specification demonstrated possession of the claimed invention and whether the disclosure enabled the full scope of the asserted claims. These requirements are distinct:

• Written description asks whether the specification shows that the inventor possessed the claimed subject matter at the relevant filing date.
• Enablement asks whether a skilled person could practice the full claimed invention without undue experimentation.

For biotechnology patents, a broad functional claim can create a substantial § 112 risk. A specification may disclose a desired function, such as glyphosate resistance, without adequately identifying the full range of DNA sequences, proteins, plant cells, or transformation methods capable of producing that function.

The district court ruled in Syngenta’s favor on the central patent-validity issues. The decision treated Monsanto’s broad claim scope as exceeding what the specification adequately described and enabled.

What did the Federal Circuit decide in 2007?

The Federal Circuit reviewed the dispute in Monsanto Co. v. Syngenta Seeds, Inc., 503 F.3d 1352 (Fed. Cir. 2007). The appellate decision is principally associated with the application of the written-description requirement to broad biotechnology claims.

The Federal Circuit held that a patent specification must reasonably convey to skilled persons that the inventor possessed the claimed invention as of the filing date. A functional description may be insufficient when it attempts to cover a large genus of biological materials without providing adequate representative species, structural information, or other evidence showing possession of the genus.

The court’s reasoning limited Monsanto’s ability to rely on the general concept of glyphosate resistance to support broad claims covering diverse genetic implementations. The decision reinforced several principles relevant to agricultural biotechnology:

1. A patent does not automatically support every biological material that performs the disclosed function.
2. Broad genus claims require an adequate description of the genus.
3. A specification may need representative examples or identifying characteristics that distinguish the claimed genus from unclaimed subject matter.
4. The written-description requirement applies independently of enablement.
5. Commercial success or later-developed technology does not cure an inadequate original disclosure.

The Federal Circuit’s decision preserved the central limitation on Monsanto’s asserted patent position. The case is widely cited in patent-law analysis involving genus claims, functional claiming, and biotechnology disclosures.

How did the case affect biotechnology patent strategy?

The litigation created a material distinction between discovering a useful biological function and adequately claiming every biological implementation of that function.

A company developing genetically modified seed technology may identify a trait, such as glyphosate tolerance, before it has characterized all genes, proteins, promoters, vectors, transformation techniques, and crop species that can produce the trait. A patent application directed only to the function may not support later claims covering all implementations.

The Monsanto-Syngenta decisions support a more detailed drafting strategy:

• Include multiple representative genes and sequences.
• Describe sequence identity and sequence similarity ranges.
• Identify conserved structural regions.
• Provide examples across relevant crop species.
• Disclose transformation methods and expression-control elements.
• Tie functional limitations to structural characteristics.
• Claim specific events, constructs, promoters, and plant varieties separately.
• File continuation applications before commercial development narrows the remaining claim strategy.

This approach reduces the risk that a later court will characterize the claims as an unsupported attempt to capture an entire technological field.

What patent litigation issues affected Syngenta’s commercial products?

The commercial significance centered on whether Syngenta’s glyphosate-resistant seed technology could be sold without infringing Monsanto’s claims. The case did not turn solely on whether Syngenta’s crops performed the same commercial function as Monsanto’s technology. It turned on whether Syngenta’s specific technology fell within valid and enforceable patent claims.

That distinction matters in crop biotechnology. Competing products may offer the same agronomic trait while using different:

• EPSPS genes;
• promoter systems;
• transformation events;
• vector configurations;
• plant species;
• insertion sites;
• breeding methods; or
• regulatory constructs.

A functionally similar product can avoid infringement if the asserted claims are limited to particular genetic structures. Conversely, broad claims can create substantial freedom-to-operate exposure if they survive written-description and enablement scrutiny.

Was there a Paragraph IV challenge in this case?

No. Paragraph IV certification is a Hatch-Waxman mechanism used in abbreviated new drug application litigation. Monsanto v. Syngenta Seeds involved agricultural biotechnology patents and genetically modified seed products, not an FDA-approved small-molecule drug.

The case therefore did not involve:

• an ANDA;
• a Paragraph IV certification;
• an Orange Book listing;
• FDA drug exclusivity;
• pharmaceutical generic entry; or
• a biosimilar application under the Biologics Price Competition and Innovation Act.

The relevant market-entry issue was seed commercialization and agricultural biotechnology freedom to operate, not generic-drug substitution.

What was the Orange Book and FDA status?

The ’605 patent had no Orange Book status. The Orange Book lists patents associated with approved prescription drug products. Seed traits and genetically modified crop events are outside that framework.

Agricultural biotechnology products are regulated through a different system involving agencies such as the U.S. Department of Agriculture, the Environmental Protection Agency, and the FDA, depending on the product and its characteristics. Those regulatory processes are separate from the patent-validity issues decided in the Monsanto-Syngenta litigation.

When did Monsanto’s patent protection expire?

The ’605 patent issued in 1994. Its ordinary patent term was governed primarily by the pre-1995 term rules, which generally provided 17 years from issuance, subject to any applicable adjustments or extensions. On that basis, the patent’s ordinary term ran into 2011.

The reported decisions do not establish a pharmaceutical-style market-exclusivity date, and the case did not involve pediatric exclusivity, new chemical entity exclusivity, or other FDA exclusivity periods. Any assessment of historical infringement exposure must distinguish the patent’s enforceable term from later regulatory or commercial protection for particular seed events and products.

How strong was Monsanto’s patent estate?

The litigation showed that Monsanto’s commercial position could be stronger than the position of a single broad patent claim. Even when a broad claim faces a written-description challenge, an agricultural biotechnology company may maintain protection through a layered portfolio covering:

Protection layer	Typical subject matter
Trait patents	Herbicide tolerance or insect resistance
Gene patents	Particular EPSPS or other resistance genes
Construct patents	Promoters, coding sequences, and vectors
Event patents	Specific insertion events and genomic locations
Plant patents	Transgenic plant cells, plants, and seed
Method patents	Methods of producing or selecting resistant plants
Regulatory and contractual controls	Seed licenses, stewardship terms, and technology agreements

The Monsanto-Syngenta decision weakened the ability to rely on an expansive functional claim unsupported by adequate disclosure. It did not eliminate the value of narrower claims directed to identified sequences, constructs, transformation events, or commercial seed products.

What generic launch or competitive risks existed?

The relevant competitive risk was not a generic-drug launch. It was entry by competing seed developers and the ability of competitors to commercialize glyphosate-tolerant crops using alternative genetic constructs or events.

A competitor’s risk profile would depend on:

1. Whether Monsanto’s patent claims remained valid.
2. Whether the accused product contained the claimed genetic elements.
3. Whether the relevant patent term remained active.
4. Whether the product was covered by separate event or construct patents.
5. Whether licensing obligations restricted commercial use.
6. Whether the product received the necessary agricultural regulatory clearances.
7. Whether the competitor had access to breeding, germplasm, and manufacturing capacity.

The appellate decision reduced the risk that Monsanto could use the ’605 patent as a blanket exclusion right over all glyphosate-resistant crop technology.

Did the case involve a settlement agreement?

The reported district court and Federal Circuit opinions establish the judicial history and appellate resolution. They do not provide a complete public record of all commercial licensing arrangements, confidential settlement terms, or broader portfolio agreements between Monsanto and Syngenta.

The decision should therefore be analyzed as a patent-validity and claim-scope precedent rather than as evidence of a disclosed royalty rate, cross-license structure, or comprehensive commercial settlement.

What litigation precedent came from Monsanto v. Syngenta?

The case is most relevant to four patent-law propositions:

• Broad biotechnology claims require adequate written description.
• Functional claiming cannot automatically substitute for disclosure of a broad biological genus.
• Written description and enablement are separate requirements.
• A patent’s commercial importance does not expand its legally supported claim scope.

For portfolio owners, the case favors early filing of detailed applications with representative biological materials and continuation strategies. For challengers, it supports invalidity arguments directed at the gap between a narrow technical disclosure and a broad genus claim.

Key Takeaways

• Monsanto asserted U.S. Patent No. 5,352,605 against Syngenta Seeds in the District of Delaware.
• The dispute concerned glyphosate-resistant genetically modified crop technology, particularly EPSPS-related technology.
• The case was decided through reported district court and Federal Circuit opinions, including 443 F. Supp. 2d 636 and 503 F.3d 1352.
• The central issue was whether Monsanto’s broad biotechnology claims satisfied written-description and enablement requirements.
• The Federal Circuit limited the use of broad functional claiming to cover a large genus of biological materials.
• The case involved no Orange Book listing, Paragraph IV certification, pharmaceutical exclusivity, or biosimilar pathway.
• The decision reduced the exclusionary reach of Monsanto’s broad patent position while leaving room for narrower patents covering specific genes, constructs, transformation events, and seed products.

FAQs About Monsanto Company v. Syngenta Seeds

What was Monsanto’s main patent in the Syngenta litigation?

The principal patent was U.S. Patent No. 5,352,605, directed to glyphosate-resistant plants and related EPSPS genetic technology.

Was Monsanto v. Syngenta a patent-infringement case or a patent-validity case?

It was both. Monsanto alleged infringement, while Syngenta challenged the asserted claims under the written-description and enablement requirements of 35 U.S.C. § 112.

Did the case concern Roundup Ready seed technology?

The dispute concerned glyphosate-resistant agricultural biotechnology associated with the same broad commercial field as Roundup Ready technology. The judicial analysis focused on the scope and validity of the asserted patent claims.

Does Monsanto v. Syngenta apply to pharmaceutical genus claims?

Yes, its written-description reasoning can apply by analogy to pharmaceutical and biotechnology genus claims, particularly when a patent claims compounds or biological materials by function without adequately disclosing the claimed genus.

Is U.S. Patent No. 5,352,605 still an active patent?

No. The patent’s ordinary term ended years after the 2007 Federal Circuit decision. Any current freedom-to-operate analysis would need to focus on later patents, continuation patents, event patents, licensing rights, and regulatory controls.

References

1. Monsanto Co. v. Syngenta Seeds, Inc., 443 F. Supp. 2d 636 (D. Del. 2006).

2. Monsanto Co. v. Syngenta Seeds, Inc., 503 F.3d 1352 (Fed. Cir. 2007).

3. U.S. Patent No. 5,352,605. (1994). U.S. Patent and Trademark Office.

4. United States Code, Title 35, Section 112. Patent Act disclosure and enablement requirements.